Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D08IGF
|
||||
Former ID |
DNC000852
|
||||
Drug Name |
L-685,818
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [537853] | ||
Structure |
Download2D MOL |
||||
Formula |
C43H69NO13
|
||||
Canonical SMILES |
CCC1C=C(C(C(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C<br />(C(CC1=O)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC)C)O)C
|
||||
InChI |
1S/C43H69NO13/c1-10-29-18-23(2)37(48)24(3)19-35(54-8)39-36(55-9)20-26(5)43(52,57-39)40(49)41(50)44-16-12-11-13-30(44)42(51)56-38(27(6)32(46)22-33(29)47)25(4)17-28-14-15-31(45)34(21-28)53-7/h17-18,24,26-32,34-39,45-46,48,52H,10-16,19-22H2,1-9H3/b23-18+,25-17+/t24-,26+,27+,28?,29+,30-,31+,32-,34+,35-,36-,37+,38+,39+,43+/m0/s1
|
||||
InChIKey |
NOQNPBXNHMZMTC-AFKHLADTSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Calcineurin | Target Info | Inhibitor | [534961] | |
Kappa-type opioid receptor | Target Info | Antagonist | [537853] | ||
KEGG Pathway | MAPK signaling pathway | ||||
Calcium signaling pathway | |||||
cGMP-PKG signaling pathway | |||||
Oocyte meiosis | |||||
Apoptosis | |||||
Wnt signaling pathway | |||||
Axon guidance | |||||
VEGF signaling pathway | |||||
Osteoclast differentiation | |||||
Natural killer cell mediated cytotoxicity | |||||
T cell receptor signaling pathway | |||||
B cell receptor signaling pathway | |||||
Long-term potentiation | |||||
Glutamatergic synapse | |||||
Dopaminergic synapse | |||||
Oxytocin signaling pathway | |||||
Glucagon signaling pathway | |||||
Alzheimer's disease | |||||
Amyotrophic lateral sclerosis (ALS) | |||||
Amphetamine addiction | |||||
Tuberculosis | |||||
HTLV-I infectionhsa04080:Neuroactive ligand-receptor interaction | |||||
WikiPathways | Mitochondrial Gene Expression | ||||
MAPK Signaling Pathway | |||||
G Protein Signaling Pathways | |||||
Cardiac Hypertrophic Response | |||||
Fc epsilon receptor (FCERI) signaling | |||||
Signaling by the B Cell Receptor (BCR) | |||||
T-Cell Receptor and Co-stimulatory Signaling | |||||
Amyotrophic lateral sclerosis (ALS) | |||||
Spinal Cord Injury | |||||
Alzheimers Disease | |||||
miR-targeted genes in muscle cell - TarBase | |||||
miR-targeted genes in lymphocytes - TarBase | |||||
Opioid Signalling | |||||
MicroRNAs in cardiomyocyte hypertrophy | |||||
Physiological and Pathological Hypertrophy of the HeartWP455:GPCRs, Class A Rhodopsin-like | |||||
Peptide GPCRs | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
Ref 534961 | Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother. 2000 Mar;44(3):739-46. | ||||
Ref 537853 | FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. J Biol Chem. 1993 May 25;268(15):11335-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.